What's Happening?
The U.S. Department of the Treasury has issued a Proposed Rule to implement the Comprehensive Outbound Investment National Security (COINS) Act, specifically targeting outbound investments in biotechnology. This rule aims to prevent U.S. investment from
aiding foreign adversaries in advancing their military, intelligence, surveillance, or cyber-enabled capabilities. While the COINS Act did not initially designate biotechnology as a prohibited sector, the Treasury is now proposing its inclusion, alongside high-performance computing, supercomputing, and hypersonic systems. The Proposed Rule outlines prohibitions on certain direct or indirect 'covered national security transactions' involving U.S. persons and specific biotechnology companies or platforms in 'Countries of Concern,' which include China (including Hong Kong and Macau), Cuba, Iran, North Korea, and Russia. These transactions encompass equity investments, equity-like debt, and qualifying joint ventures. The public comment period for this Proposed Rule is open until December 7, 2026.
Why It's Important?
This Proposed Rule signifies a growing concern within both the Executive and Legislative branches regarding the national security risks posed by certain biotechnology developments in China and other adversarial nations. By restricting U.S. investment in these areas, the government aims to safeguard critical U.S. technological advantages and prevent their misuse by foreign powers. The move follows previous legislative efforts like the Biotech Investment National Security Act of 2026 (BINSA) and the 2025 BIOSECURE Act, which restricted federal funding for certain biotechnology products from entities deemed national security threats. The broad scope of prohibited biotechnologies, ranging from genetic engineering to brain-computer interfaces and advanced biomanufacturing equipment, indicates a comprehensive strategy to control the flow of capital and expertise. This could significantly impact U.S. biotechnology companies and investors with existing or planned collaborations in these regions, requiring careful analysis of transaction structures to ensure compliance.
What's Next?
The Proposed Rule is currently open for public comments until December 7, 2026, allowing industry stakeholders to provide input and potentially shape the final regulations. Following this period, the Treasury will issue final regulations, which will then become effective. Companies with existing collaborations or contemplating new transactions in biotechnology, particularly with entities in 'Countries of Concern,' will need to meticulously review their arrangements. The Proposed Rule also establishes a mechanism for parties to request confidential feedback from the Treasury on prospective transactions, though this feedback would be non-binding. The implementation of these restrictions will likely lead to a re-evaluation of global investment strategies for many U.S. biotechnology firms and investors, potentially shifting focus away from certain foreign markets.
Beyond the Headlines
The inclusion of biotechnology as a prohibited sector for outbound investment highlights a broader strategic shift in U.S. national security policy, recognizing the dual-use nature of advanced biotechnologies. This move underscores the increasing importance of biological capabilities in modern warfare and intelligence, extending beyond traditional military hardware. The emphasis on preventing the transfer of technical knowledge and capabilities, even through seemingly innocuous joint ventures or licensing agreements, reflects a proactive approach to intellectual property protection and technological leadership. This policy could also spur increased domestic investment and innovation in biotechnology, as U.S. companies may seek to develop capabilities internally or with trusted partners to avoid foreign entanglements. The long-term implications could include a more bifurcated global biotechnology landscape, with distinct ecosystems developing in the U.S. and its allies versus 'Countries of Concern,' potentially impacting global scientific collaboration and drug development.
